Suppressing Colon Cancer Development With Nanotechnology: A Plant-Mediated Approach Under Investigation
Plant medicine and nanotechnology meet at an interesting scientific question: can plant-assisted materials change the conditions that allow cancer to develop? Answering it requires looking beyond whether a substance kills cells in a dish. We need to understand what happens to inflammation, tissue integrity, genetic damage, and the body’s ability to remove abnormal cells.
In July 2026, Badmus and colleagues reported preliminary colon protection using Vachellia sieberiana-mediated zinc oxide nanoparticles in rats. The experiment examined precancerous injury, rather than treatment of human cancer. [1]
Thirty-five male Wistar rats, five per group, received oral doses of 100, 200, or 400 mg/kg, beginning one week before 1,2-dimethylhydrazine/dextran sodium sulphate exposure. At 400 mg/kg, reductions versus chemically exposed controls were: [1]
| Measured endpoint | Reported reduction |
|---|---|
| Interleukin-1 beta (inflammation) | 27.22% |
| Tumour necrosis factor-alpha (inflammation) | 16.27% |
| 8-OHdG (oxidative DNA damage) | 36.72% |
| TBARS (lipid peroxidation) | 79.6% |
Other findings included improved tissue architecture and glutathione-related measures, increased DNA fragmentation, and no significant superoxide dismutase effect. These are biomarker changes. The abstract reverses cytokine induction figures; this table follows the detailed results. [1]
That combination invites a broader scientific discussion. How might an engineered material protect injured tissue, and how would we determine whether that protection changes cancer outcomes? Those questions connect this experiment to a much larger body of research.
Green synthesis describes the use of biological materials during nanoparticle production. In a separate experiment, Selim and colleagues used an aqueous extract of Deverra tortuosa to produce zinc oxide nanoparticles, with plant constituents serving as synthesis and capping agents. Capping refers to molecules associated with a particle’s surface that help influence its stability and interactions. Their work illustrates plant chemistry’s participation in manufacturing a material. [2]
This distinction matters when interpreting plant-based nanomedicine. A manufactured particle and the original extract are different experimental preparations. Evidence for one cannot automatically establish the effects of the other. Likewise, demonstrating a synthesis method does not establish clinical usefulness. For a researcher, the important question becomes which properties of the finished material account for its biological activity.
Inflammation offers one possible point of intervention. In experimental colitis-associated cancer, Grivennikov and colleagues showed that interleukin-6, or IL-6, supports intestinal epithelial cell survival and proliferation through the transcription factor STAT3. A transcription factor helps regulate which genes a cell uses. In this setting, inflammatory signals can help premalignant cells survive and expand. [3]
The same work also showed the complexity of that biology: removing IL-6 or epithelial STAT3 increased susceptibility to acute intestinal injury. Signals that can support tumour development also participate in tissue protection. Successful intervention therefore requires attention to timing, location, and cellular context. Preserving useful repair while limiting tumour-promoting signalling is a more demanding task. [3]
Oxidative damage adds another layer. Reactive oxygen and nitrogen species are chemically reactive molecules that can damage DNA when their production and removal become unbalanced. Meira and colleagues tested the importance of this damage in mice with impaired activity of the DNA repair enzyme alkyladenine DNA glycosylase, abbreviated Aag. Inflammation-associated DNA lesions accumulated more extensively in repair-deficient animals, which also developed more severe colon pathology and tumour formation under the experimental conditions. [4]
That study supports a causal role for inflammation-associated genetic injury in its models. It also helps explain why researchers measure chemical damage to DNA rather than looking only at visible tissue changes. However, a damage marker and a cancer outcome answer different questions. As a scientific interpretation, a lower marker can justify investigating protection, while a prevention claim requires demonstrating fewer clinically meaningful lesions or cancers over time.
Zinc oxide research also presents an apparent puzzle: why investigate a material for reducing oxidative injury when other experiments use it to generate oxidative stress in cancer cells?
Hanley and colleagues reported that zinc oxide nanoparticles preferentially killed cancerous T cells compared with normal resting T cells in laboratory experiments. Reactive oxygen species contributed to cell death, and inhibiting those species was protective. Activated normal T cells were also more susceptible than resting cells. This was a study of particular immune-cell populations, not evidence of universal selectivity for every cancer type. [5]
The scientific lesson is that selectivity must be measured. Cell state matters, and a material capable of damaging malignant cells can also affect other biologically active cells. My interpretation is that broad claims such as “nanoparticles protect healthy cells and destroy cancer cells” skip the experimental work needed to establish where that distinction actually holds.
Research directly involving colorectal cancer cells provides additional context. Berehu and Patnaik investigated zinc oxide nanoparticles synthesized using Tinospora cordifolia. They reported reduced viability in HCT-116 and Caco-2 colorectal cancer cells, increased reactive oxygen species, changes in mitochondrial membrane potential, and evidence of cell death. The concentrations associated with 50% inhibition of the viability readout were approximately 31.4 and 36.7 micrograms/mL, respectively. [6]
Those findings describe a different formulation and experimental setting. They help explain why oxidative stress is not inherently a benefit or a harm independent of context. Deliberately overwhelming a cancer cell’s defences and protecting an injured tissue are separate objectives. Whether one formulation can achieve both selectively would require direct testing. A shared ingredient name does not establish a shared mechanism.
Apoptosis, the regulated process by which cells dismantle themselves, is another area where precision matters. In evaluating a candidate material, I would want several complementary measurements: cell-specific imaging, membrane changes, cleavage of relevant proteins, and direct measures of survival. Fragmented DNA can contribute to that assessment, but the crucial question remains which cells are dying and through what process.
A stronger experiment would distinguish abnormal epithelial cells from normal epithelial cells and infiltrating immune cells. It would also test whether blocking a proposed pathway changes the response. That approach moves the argument from “these events occurred together” toward evidence that one event helped cause another. This is the kind of mechanistic work I would prioritize before describing an intervention as selectively anticancer.
Early structural changes require similar care. Aberrant crypt foci are clusters of abnormal intestinal glands used in colon carcinogenesis research. Their interpretation depends on the model and the type of lesion. In a human substudy of the Adenoma Prevention with Celecoxib trial, Cho and colleagues examined rectal aberrant crypt foci in 45 participants. The sampled lesions were nondysplastic, and their presence or number did not accurately predict recurrent adenomas. [7]
That finding does not invalidate every use of crypt abnormalities in animal research. It demonstrates why an early marker needs validation for the particular outcome being claimed. A favourable microscopic appearance is useful evidence, but it cannot carry the full weight of a human cancer-prevention claim. My preferred progression would be to connect early changes with later tumour incidence, tumour burden, and durable outcomes in the same research programme.
Safety deserves equal scientific attention. Park and colleagues conducted a 90-day oral study of a different, negatively charged, 20 nm zinc oxide nanoparticle preparation in rats. They reported stomach lesions across tested doses, pancreatic changes at the highest dose, and increased zinc concentrations in several tissues. They could not establish a no-observed-adverse-effect level within the tested range. [8]
Those results cannot be assigned directly to a plant-mediated preparation with different properties. They do show why safety must be established for the actual formulation, route, dose, and duration under investigation. A colon-focused benefit would need to be evaluated alongside effects on other organs. Neither the word “green” nor the absence of obvious short-term injury answers that question.
Characterization is therefore part of the biological argument. The MIRIBEL framework, proposed by Faria and colleagues, calls for reporting material characteristics, biological characteristics, and experimental details in bio-nano research. It emphasizes relevant properties such as composition, size, aggregation, and the difference between an administered dose and the amount reaching cells or tissues. [9]
For this research direction, I would want electron microscopy, size distributions in relevant fluids, surface chemistry, and dissolution measurements alongside the biological results. An X-ray-derived crystallite estimate answers a different question from the size of particle clusters encountered by cells. Measurements under realistic exposure conditions would help determine what the tissue actually experiences. These are practical questions about experimental identity and exposure, not decorative additions to a methods section.
The next studies should separate the contributions of the botanical extract, dissolved zinc, and the particulate material. I would compare the finished formulation with extract alone, an appropriate zinc salt, and suitably matched zinc oxide controls. These comparisons could test whether the manufacturing approach provides an advantage and whether the combined preparation produces an effect beyond its individual components.
I would also separate prevention experiments from treatment experiments. One programme could investigate whether an intervention changes the emergence of lesions; another could begin only after pathology is established. Using both sexes, independent production batches, blinded tissue assessment, prespecified primary outcomes, and adequately justified sample sizes would make the resulting evidence easier to trust and reproduce.
Finally, a proposed colon-directed material should be tracked through the digestive environment. I would want to know how much remains particulate, how much dissolves, where the material or released zinc travels, and what happens after repeated exposure stops. Human-derived colon organoids and carefully chosen animal models could help narrow those questions before a clinical programme is considered.
What interests me about plant-mediated nanotechnology is the opportunity to test a biological idea with an engineered material whose properties can be measured and refined. That opportunity comes with an obligation to be equally precise about the evidence. A promising laboratory signal earns the next experiment. Progress toward medicine comes when reproducible benefit, a defensible mechanism, and a usable safety margin begin to tell the same story.
By Mike Robinson, Researcher
Global Cannabinoid Research Center
References
- Badmus JA, Afolabi OD, Adedeji AL, et al. Green-synthesized Vachellia sieberiana-Zinc oxide nanoparticles suppress inflammation and oxidative DNA damage in premalignant colon. Academia Nano: Science, Materials, Technology. 2026;3(3). Published July 3, 2026. https://doi.org/10.20935/AcadNano8404.
- Selim YA, Azb MA, Ragab I, Abd El-Azim MHM. Green synthesis of zinc oxide nanoparticles using aqueous extract of Deverra tortuosa and their cytotoxic activities. Scientific Reports. 2020;10:3445. https://doi.org/10.1038/s41598-020-60541-1.
- Grivennikov S, Karin E, Terzic J, et al. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103-113. https://doi.org/10.1016/j.ccr.2009.01.001.
- Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. Journal of Clinical Investigation. 2008;118(7):2516-2525. https://doi.org/10.1172/JCI35073.
- Hanley C, Layne J, Punnoose A, et al. Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles. Nanotechnology. 2008;19(29):295103. https://doi.org/10.1088/0957-4484/19/29/295103.
- Berehu HM, Patnaik S. Biogenic zinc oxide nanoparticles synthesized from Tinospora cordifolia induce oxidative stress, mitochondrial damage and apoptosis in colorectal cancer. Nanotheranostics. 2024;8(3):312-329. https://doi.org/10.7150/ntno.84995.
- Cho NL, Redston M, Zauber AG, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prevention Research. 2008;1(1):21-31. https://doi.org/10.1158/1940-6207.CAPR-07-0011.
- Park HS, Shin SS, Meang EH, et al. A 90-day study of subchronic oral toxicity of 20 nm, negatively charged zinc oxide nanoparticles in Sprague Dawley rats. International Journal of Nanomedicine. 2014;9(Suppl 2):79-92. https://doi.org/10.2147/IJN.S57926.
- Faria M, Björnmalm M, Thurecht KJ, et al. Minimum information reporting in bio-nano experimental literature. Nature Nanotechnology. 2018;13(9):777-785. https://doi.org/10.1038/s41565-018-0246-4.
Share It:
Tags:
Leave A Comment